Algernon Pharmaceuticals Inc. C.AGN

Alternate Symbol(s): AGNPF

Algernon Pharmaceuticals Inc. is a clinical-stage drug development company. The Company is focused on developing repurposed therapeutic drugs in the areas of non-alcoholic steatohepatitis (NASH), a type of liver disease, chronic kidney disease (CKD), inflammatory bowel disease (IBD), idiopathic pulmonary fibrosis (IPF) and chronic cough as well as advancing a stroke program using N, N-Dimethyltryptamine (DMT). The Company operates through two segments, which includes the development of repurposed therapeutic drugs in Canada and the facilitation of the Company’s lead drug candidates into off-label phase II clinical trials (humans) in Australia. The Company's pipeline includes NP-251 (Repirinast) and AP-188 (DMT). The Company, through its subsidiary, Algernon NeuroScience Inc., is developing AP-188 (DMT) as a potential treatment for stroke and traumatic brain injury (TBI) recovery. Its NP-251 is being developed as a potential treatment for kidney inflammation and fibrosis.

CSE:AGN - Post by User

Algernon Pharmaceuticals Inc. > 6 Fold Dilution To Chase After COVID-19. End Of Story.

<< Previous

Bullboard Posts

Next >>

Comment by TheBearInTheWoodson Jul 06, 2021 3:22pm

94 Views

Post# 33500094

RE:RE:RE:RE:RE:6 Fold Dilution To Chase After COVID-19. End Of Story.

To be clear ,

I believe that the chronic cough trial has had an outcome that has not been disclosed to the market. Rather negative or neutral outcome that has stalled the trial, there is no other reason for such a long delay. How you put any hope in this management team is beyond me, but to each their own.

<< Previous

Bullboard Posts

Next >>

Sirios Resource discovers visible gold in Quebec